Pelvic pain is the main clinical manifestation associated with endometriosis, a disorder caused by endometrial tissues growing outside the uterus. Pain relievers, hormonal contraceptives, aromatase inhibitors, androgenic agents, and gonadotropin-releasing hormone (Gn-RH) agonists are currently used to manage endometriosis-associated pelvic pain. However, more-efficacious and more easily administered medical options remain a high unmet need. The launches of second-generation, orally administered Gn-RH antagonists will significantly expand the endometriosis therapeutic market by 2026.
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Six country-specific interviews with endometriosis specialists.
Epidemiology: Diagnosed and drug-treated prevalent cases.
Emerging therapies: Phase III/PR: 2; Phase II: 3; coverage of select preclinical and Phase I products.
Market forecast: Drug-level sales and patient share of key endometriosis therapies in 2026.
Key companies: AbbVie, Bayer, Myovant, ObsEva, Repros.
Key drugs: elagolix, relugolix, OBE-2109, leuprolide, telapristone, vilaprisan.